Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05490030

Enrollment

Registered

2022-08-05

Start date

2025-03-06

Completion date

2025-06-26

Last updated

2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Impairment

Keywords

Hepatic, Impairment, TNO155, Phase 1, pharmacokinetics, safety, Tolerability, Child-Pug

Brief summary

The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

Detailed description

This is a study to evaluate the PK of TNO155 in participants with mild, moderate or severe hepatic impairment compared to matched healthy control participants with normal hepatic function. The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment (mild, moderate, or severe) according to a classification score determined at the screening visit and confirmed unchanged at the baseline visit. Each participant in the healthy control group may be matched to 1 or more evaluable participants with hepatic impairment with respect to age (± 10 years), body weight (± 20%), sex and smoking status (smoker vs. non smoker). Each participant in the control group can be matched to participants from any hepatic impairment group but cannot be matched to more than 1 participant from the same hepatic impairment group. All participants will be domiciled from Day -1 until Day 11. All participants should have a poststudy safety follow-up contact conducted approximately 30 days after administration of study treatment. The study will be considered complete once all the participants have finished the required assessments, dropped out, or been lost to follow-up before completing the required assessments.

Interventions

DRUGTNO155

Single oral dose of TNO155 on Day 1

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment according to the Child Pugh classification score determined at the screening visit and confirmed unchanged at the baseline visit. Healthy participants who were identified and enrolled as matching partners for a hepatic impairment group in Part I can serve as matching partners for participants in hepatic impairment group in Part II if they fulfilled the matching criteria. Otherwise, additional matched healthy participants will be enrolled. Part I: will include participants with mild and moderate levels of hepatic impairment as well as healthy control participants assigned to the groups Part II: will include participants with severe hepatic impairment.

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

All participants Participants must weigh at least 50 kg and no more than 120 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, for healthy participants. For participants with hepatic impairment without overt ascites, the BMI should be within the range of 18.0 to 40.0 kg/m2. For participants with hepatic impairment with overt ascites, the BMI should be within the range of 18.0 to 45.0 kg/m2. Group 1 •Each healthy control participant must match in age (± 10 years), sex, body weight (± 20%), and smoking status to at least 1 hepatic impairment participant in Groups 2, 3 and/or 4. Groups 2 to 4 •Participants with mild, moderate or severe hepatic impairment must have a Child-Pugh score clinically determined at screening and confirmed unchanged at baseline calculated as per the Child-Pugh classification in line with the hepatic impairment status of each Group

Exclusion criteria

All Participants * Use of drugs (prescription, non-prescription and herbal remedies such as St John's wort) known to affect CYP3A or UGT1A3, including UGT1A3 inhibitors and inducers and strong and moderate CYP3A inhibitors and inducers, within 4 weeks prior to dosing until completion of the End of Study Visit. * Acute or chronic hepatitis B or C infection or active infection requiring therapy that will not be completed before screening. Left ventricular ejection fraction (LVEF) \< 50% or below the institutional standard lower limit, whichever is higher, as determined by multiple gated acquisition (MUGA) scan or Trans-thoracic echocardiography (TTE) at screening or baseline. •At screening, history of retinal vein occlusion (RVO) or presence of predisposing factors to RVO or central serous retinopathy, or any other clinically significant ophthalmologic abnormalities determined by an ophthalmologist. Group 1 * Any single parameter of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) exceeding 2.5 × upper limit of normal (ULN) or total bilirubin ≥ 1.5 ULN OR any elevation above ULN of more than 1 parameter of ALT, AST, GGT, ALP, or serum bilirubin at screening or baseline. * Impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen and/or other urea values outside local laboratory ranges or abnormal urinary constituents at screening or baseline. Groups 2 and 3 * Severe complications of liver disease within the preceding 3 months prior to dosing. * Hospitalization due to liver disease within the preceding 1 month prior to dosing. * Participant has received liver transplant at any time in the past and is on immunosuppressant therapy. * Participants requiring paracentesis more than every 3 weeks for the management of ascites are excluded. Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Apparent volume of distribution during terminal phase (Vz/F) of TNO155	Up to 240 hours post single dose	Vz/F will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155	Up to 240 hours post single dose	AUClast will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
AUC from time zero to time t (AUC0-t) of TNO155	Up to 240 hours post single dose	AUC0-t will be calculated as needed based on TNO155 plasma concentrations and non-compartmental methods. The definition of time t may be data-driven post-hoc to mitigate treatment bias due to within participant differences in Tlast between the treatments, or may be selected to allow between-study exposure comparisons that use a common time window.
AUC from time zero to infinity (AUCinf) of TNO155	Up to 240 hours post single dose	AUCinf will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
Maximum (peak) observed plasma concentration (Cmax) of TNO155	Up to 240 hours post single dose	Cmax will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
Time to reach maximum observed plasma concentration (Tmax) of TNO155	Up to 240 hours post single dose	Tmax will be calculated based on TNO155 plasma concentrations and non-compartmental methods
Elimination half-life (T1/2) of TNO155	Up to 240 hours post single dose	T1/2 will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
Sampling time of the last measurable plasma concentration (Tlast) of TNO155	Up to 240 hours post single dose	Tlast will be calculated based on TNO155 plasma concentrations and non-compartmental methods.
Apparent plasma clearance (CL/F) of TNO155	Up to 240 hours post single dose	CL/F will be calculated based on TNO155 plasma concentrations and non-compartmental methods.

Secondary

Measure	Time frame	Description
Unbound Cmax (Cmax,u) of TNO155	Up to 240 hours post single dose	Cmax,u will be calculated based on the unbound fraction of TNO155 in plasma.
Unbound AUClast (AUClast,u) of TNO155	Up to 240 hours post single dose	AUClast,u will be calculated based on the unbound fraction of TNO155 in plasma.
Unbound AUCinf (AUCinf,u) of TNO155	Up to 240 hours post single dose	AUCinf,u will be calculated based on the unbound fraction of TNO155 in plasma
Unbound CL/F (CL/F,u) of TNO155	Up to 240 hours post single dose	CL/F,u will be calculated based on the unbound fraction of TNO155 in plasma.
Renal clearance (CLr) of TNO155	Up to 240 hours post single dose	CLr will be calculated based on urinary excretion data of TNO155.
Apparent non-renal clearance (CLNR/F) of TNO155	Up to 240 hours post single dose	CLNR/F will be calculated based on urinary excretion data of TNO155.
Fraction of dose excreted in urine (fe) of TNO155	Up to 240 hours post single dose	Fe will be calculated based on urinary excretion data of TNO155.
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	Up to 30 days post single dose	Incidence of AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026